A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Inclusion Criteria: * Written informed consent must be provided. * Males and females age ≥ 18 years; * Histopathologically documented primary or secondary AML, as defined by WHO criteria, confirmed by pathology review at treating institution, meeting at least one of the following: 1. Refractory to at least 1 cycle of induction chemotherapy, or 2. Relapsed after at least 1 cycle of induction chemotherapy, or 3. Patient is not, according to the clinical judgment of the Principal Investigator, a candidate for induction chemotherapy due to age, comorbidity, or other factors; * Eastern Cooperative Oncology Group (ECOG) performance status of 0-3; * In the absence of rapidly progressing disease, the interval from prior treatment to time of SKLB1028 administration should be at least 2 weeks for cytotoxic agents, or at least 5 half-lives for noncytotoxic agents; * Serum creatinine ≤1.5 × ULN; * Total serum bilirubin ≤ 1.5 × ULN unless considered due to Gilbert's syndrome or leukemic organ involvement; * Serum AST or ALT ≤ 3.0 × ULN unless considered due to leukemic organ involvement; * Females of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study; Exclusion Criteria: * Histologic diagnosis of acute promyelocytic leukemia; * Clinically active central nervous system leukemia; * Persistent clinically significant toxicity from prior chemotherapy that is Grade 2 or higher; * Bone marrow transplant within 100 days prior to study; * Active, uncontrolled infection; * Major surgery within 4 weeks prior to study; * Radiation therapy within 4 weeks prior to study; * Left ventricular ejection fraction ≤1 × ULN,or﹤50%. Clinically significant ECG QTc prolongation (Male: \>450ms, Female: \>470ms).Significant cardiac disease. * Human immunodeficiency virus positivity; * Active hepatitis B or C or other active liver disease; * Women who are pregnant, lactating; * Medical condition, serious intercurrent illness, or other extenuating circumstance that, in the judgment of the Principal Investigator, could jeopardize patient safety or interfere with the objectives of the study.